4//SEC Filing
Suria Hamza 4
Accession 0001209191-21-070986
CIK 0001370053other
Filed
Dec 21, 7:00 PM ET
Accepted
Dec 22, 6:42 PM ET
Size
13.9 KB
Accession
0001209191-21-070986
Insider Transaction Report
Form 4
ANAPTYSBIO, INCANAB
Suria Hamza
DirectorPresident, CEO
Transactions
- Sale
Common Stock
2021-12-20$35.75/sh−19,208$686,776→ 74,122 total - Exercise/Conversion
Employee Stock Option (Right to Buy)
2021-12-20−36,645→ 0 totalExercise: $1.12Exp: 2022-01-31→ Common Stock (36,645 underlying) - Sale
Common Stock
2021-12-20$34.89/sh−11,915$415,756→ 93,330 total - Sale
Common Stock
2021-12-20$36.40/sh−5,522$201,026→ 68,600 total - Exercise/Conversion
Common Stock
2021-12-20$1.12/sh+36,645$41,042→ 105,245 total
Footnotes (6)
- [F1]The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.25 to $35.23, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.26 to $36.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.26 to $36.52, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
- [F5]The stock option grant was issued on February 1, 2012, is fully vested and exercisable until its expiration date of January 31, 2022.
- [F6]In addition to the remaining options to purchase 0 shares of common stock as set forth in Table II above, the Reporting Person also holds (i) additional options to purchase up to an aggregate of 1,118,893 shares of common stock, which options vest according to their terms, and (ii) 68,600 shares of common stock held directly.
Documents
Issuer
ANAPTYSBIO, INC
CIK 0001370053
Entity typeother
Related Parties
1- filerCIK 0001654495
Filing Metadata
- Form type
- 4
- Filed
- Dec 21, 7:00 PM ET
- Accepted
- Dec 22, 6:42 PM ET
- Size
- 13.9 KB